Loading

JSM Gastroenterology and Hepatology

Infectious Endocarditis in Patients with Cirrhosis: Epidemiology, Characteristics and Outcome

Review Article | Open Access

  • 1. Service d’hépato-gastro-entérologie et Nutrition, CHU Côte de Nacre, France
  • 2. Service d’hépato-gastro-entérologie de Nutrition et d’Alcoologie, GHPSO, France
+ Show More - Show Less
Corresponding Authors
Allaire Manon, Service d’Hépato-Gastroentérologie et de Nutrition GHPSO, CHU Côte de Nacre, 14000 CAEN, France, Tel: 33 2 31 06 45 43 ; Fax : 33 2 31 06 45 45.
Abstract

Bacterial infections are frequent in patients with cirrhosis with a 4-fold increase mortality. Spontaneous bacterial peritonitis, urinary tract infections and pneumonia are the most common infections observed but few data concerning infectious endocarditis (IE) are available. Some old studies suggested a higher prevalence of IE in patients with cirrhosis compared to general population. Regarding clinical features, patients were usually men, older than 55 years old with an alcoholic cirrhosis and a cardiopathy history. IE were mostly located on aortic and mitral valve. Gram positive bacteria were involved in 74-100% of cases with about 26-80% of Staphylococcus aureus, due to nosocomial infections. Enterococci and Gram negative bacteria were observed respectively in 6-19% and 3-5% of cases. Compared to general population, fewer patients underwent cardiac valve surgery, a fact grossly related toliver insufficiency. Selection criteria for surgery have to be refined since postoperative mortality could be less than 10% in selected cirrhotic patients with liver insufficiency. Mortality rates were high and associated with the severity of the liver disease. A prothrombin time ≤40% appeared as an independent risk factor of mortality.

Citation

Allaire M, Ollivier-Hourmand I, Garrioud A, Dao T, Cadranel JF (2017) Infectious Endocarditis in Patients with Cirrhosis: Epidemiology, Characteristics and Outcome. JSM Gastroenterol Hepatol 5(1): 1077.

Keywords

•    Infectious endocarditis
•    Cirrhosis
•    Epidemiology
•    Treatment
•    Prognosis

ABBREVIATIONS

IE: Infectiousendocarditis; LPS: Lipopolysaccharide; OR: Odd Ratio; PT: Prothrombin Time

INTRODUCTION

Due to an immunocompromised state, patients with cirrhosis are prone to bacterial infections and consequently to develop sepsis, sepsis-induced organ failure and death [1]. Some risk factors are clearly identified such as chronic alcohol intake [2,3], degree of hepatic insufficiency [2,3] and intestinal bleeding [4]. Recently, new risk factors have been discussed such as diabetes mellitus [5], chronic use of proton pump inhibitors [6,7] and positive viral load in case of chronic hepatitis C infection [7]. The most common infections observed in case of cirrhosis are spontaneous bacterial peritonitis, urinary tract infections, pneumonia, septicemia and soft tissue infections. Bacterial infections are the first cause of acute or chronic liver failure and account for a 4 fold higher mortality ratecompared to general population, estimated to 30% at 1 month and 63% at 1 year [8].

Various mechanisms of increased susceptibility to infections in cirrhosis have been described. Bacterial translocation, due to altered intestinal permeability and intestinal bacterial overgrowth, leads to chronic exposure to pathogen-associated molecular patterns such as lipopolysaccharides (LPS) and activation of related pattern-recognition receptors like LPS toll-like receptor-4 which induce an inadequate release of proinflammatory cytokines called cytokine storm. This state is also facilitated by porto systemic shunts. Due to chronic inflammation, adaptative immunity cells are constantly stimulated which, by early senescence and turnover in memory T cells, leads to a decrease in total and naive T cells. An impairment of systemic reticuloendothelial system, a decrease in bactericidal capacity of phagocytic cells and a reduction in complement have also been described to explain altered innate immunity system. At the end, altered innate and adaptative immunity, cytokine storm and sepsis-induced nitric oxyd lead to inadequate tissue perfusion, organ failure and death [9-13].

Despite an improvement of the health system in the past decades, incidence of infectious endocarditis (IE) has not decreased [14-16]. This apparent paradox can be partly explained by epidemiological changes such as the emergence of new risk factors and evolution of bacterial ecology. So far, few data about IE in patients with cirrhosis are available. Some studies have shown a higher prevalence of IE and a higher mortality in case of cirrhosis compared to general population. The aims of the review were to describe epidemiological data, clinical data and prognosis of IE in patients with cirrhosis.

Infectious endocarditis in general population

In general population, the incidence of IE were estimated between 3-10 new cases per 100,000 inhabitants per year with an in-hospital mortality rate around 20% and a mortality rate of 25-30% at 6 months [14-20]. Diagnosis relies on Dukes modified criteria (Table 1) [21]. Clinical presentation is diverse andnotspecific.IE must be considered in case of Staphylococcus aureus bacteremia and sepsis with unknown origin. The majority of patients were often more than 70 years old and incidence increased with age. Sex ratio was 2 males for 1 female and about 50% of patients had underlying preexistent heart disease. Fever and heart murmur were frequent and a location on the aortic and mitral valve was observed respectively in about 35% and 20% of patients but, in case of drug addiction, tricuspid injury was more common (more than 50% of cases) [14-20].

Characteristics of patients evolved in recent decades. Indeed, until the 1970s, congenital valve diseases and chronic rheumatic heart disease were the main factors predisposing to IE. Currently, new risk factors are emerging: use of intravenous drugs, heart materials, prosthetic valves, elderly people with degenerative valve disease, cancer, haemodialysis and immunosuppression states (diabetes mellitus, HIV infection and cirrhosis). There are also an increase of nosocomial and health-care acquired IE (accounting for 25-30% of contemporary cohorts) and variation in bacterial ecology [15,18,19]. In recent series, gram-positive bacteria were the most common germs foundwith a majority of streptococci (32-58%) and Staphylococcus aureus (23-27%) and were frequently associated with invasive procedures and drug use. Enterococci were observed in 7-11% of cases and infections with Gram-negative bacilli in 3-10% of cases [15,18,19]. Potential sources of infections were usually oral, dental, intestinal, urogenital and cutaneous. Some associations were observed such as Staphylococcus aureus with invasive procedures and intravenous drug use, Streptococcus gallolyticus with digestive neoplasia and elderly population [14,15].

Treatment of IE depends on a multidisciplinary approach. Bactericidal antibiotics are a cornerstone of therapy and must be administrated according to consensus data based on empirical treatment secondarily adapted to germ and resistance profile (Table 2)[20,21]. Long term treatment and high doses must be used to ensure diffusion into the vegetations and kill dormant bacteria. Parenteral therapy is usually recommended. Surgery must be considered in case of refractory cardiac failure caused by valvular insufficiency, persistent sepsis under medical therapy and persistent life-threatening embolism. In acute infections, surgery was necessary for 25-30% of patients and for 20-40% in later phases with a survival rate at 10 years of 61% [14,15].

Septic embolisms (25-50%) and heart failure (34%) were the most common observed complications. Heart failure was the first cause of death, followed by neurological complications and uncontrolled infections. Mortality predictive factors were identified as age > 50 years old, location on prosthetic valve, heart failure, diabetes mellitus, kidney or neurological complications and virulence of the causative organism especially for Staphylococcus aureus [14,15,18,19]. Because of its severity, IE should be prevented whenever possible according to patient risk factors and type of invasive procedures.

Infectious endocarditis in patients with cirrhosis

Epidemiological data: In series of IE, the proportion of patients with cirrhosis varied from 5 to 17% [14,17,22]. So far, few studies are available regarding prevalence of IE in case of cirrhosis and three of them are not recent and conducted in autopsy series. The first one, published in 1942 reported an IE rate of 6.7% in patients with cirrhosis versus 3.4% in the control group [23]. This trend was also confirmed by Snyder et al. in 4,215 autopsied veterans (1.8% in patients with cirrhosis versus 0.9% in controls, p<0.06) [24]. However, no significance difference have been observed between the two groups in 2,350 autopsies according to Hernandez et al. [25]. So far, data based on autopsies are discordant and do not allow us to draw any conclusion.

Recently, after adjusting for age, sex and comorbidities in 81,633 patients of the National Insurance Database in Taiwan, during a follow up of three years, Hung et al. showed a higher risk of IE in case of cirrhosis (0.3%) compared to general population (0,17%, odd ratio [OR]=2.04; p<0.001) [26].

Clinical features: Regarding clinical data, several series of IE in patients with cirrhosis are available and the largest one described by our group included 101 patients [27]. As observed in general population, the average age varied between 35 and 72 years old with a sex ratio of 2 males for 1 female and a preferential location on the aortic and mitral valves. Regarding the series of patients with cirrhosis, characteristics of patients differed according to the geographic origin of the study (viral cirrhosis in Asia vs. alcohol cirrhosis in industrialized countries), the medical history (valvular prosthesis present in 12.9-25% of patients) and habits of the patients (drug addiction associated with younger patients, viral cirrhosis and tricuspid location). No difference existed according to fever and positive blood culture between general population and patients with cirrhosis [27-32].

Infectious characteristics: As in the general population, bacteriological ecology changes were also observed with time in patients with cirrhosis. In the last studies, Gram-positive bacteria (85-100%), especially Staphylococcus aureus (26-80%) predominated. Enterococci were observed only in 6-19% of cases and Gram negative bacilli were rare (3-5%) (Table 3) [28-30,32]. However, data on multidrug resistance bacteria were poorly available. Nosocomial infections were frequent and estimated to 45% in the study of Fernández Guerrero et al.[28]. Some IE were described after transjugular intrahepatic portosystemic shunt procedure, upper endoscopy and hepatic biopsies but there is no recommendation about prevention related to invasive procedures [28,33,34]. Potential source of infections were mostly oral and dental, intestinal, urogenital and cutaneous.

Medical treatment and cardiac surgery: As described in Table (2), antibiotics recommendations are available [21]. Nevertheless, in patient with cirrhosis, less aminoglycosides and rifamycin were used, probably due to their potential renal and liver toxicity [27]. As these antibiotics are a key point in treatment strategy, this issue might impact the outcome. Further studies are needed to evaluate the real impact and complications of aminoglycosides and rifamycin in patients with cirrhosis.

In series of IE patients with cirrhosis, we observed a lower rate of cardiac surgery mostly due to hepatocellular dysfunction. In fact, cardiac surgery is known to be risky in case of cirrhosis and mortality is often linked to severe liver failure secondary to extracorporeal circulation and to anesthetic drugs that decrease hepatic blood flow. Coagulopathy and thrombocytopenia associated with cirrhosis and heparin use during surgery also promote perioperative bleeding events [35,36]. In series, about 26-30% of patients with cirrhosis underwent surgical replacement compared to 42-51% in the control group [35,36]. Interestingly, in the study of Fernández Guerrero et al., valve replacement was considered in 16 patients with cirrhosis but only performed in 9 patients(Child-Pugh A: 4 out of 4,Child-Pugh B: 4out of 7, Child-Pugh C: 1 out of 5) [28]. Postoperative death occurred in 8% of patients with liver cirrhosis versus 3% in the control group in the series of Pérez de Isla et al.[32], close to our results with 9.7% of patients with cirrhosis who died just after surgery compared to 8.7% in the control group [27]. In our series, among the 10Child-Pugh C patients, who underwent surgery, 9 were still alive at time of discharge [27]. We suggest that history of cirrhosis and time of decompensation should be taken into account to evaluate liver insufficiency, A recent decompensation due to the septic state is probably less harmful than an ancient long-term decompensation and should not be considered as an absolute contraindication to surgery. Nevertheless, due to a low number of surgery events in the cirrhotic group, surgical prognosis factors have not been pointed out. Selection criteria for surgery have to be refined since postoperative mortality could be less than 10% in selected cirrhotic patients with liver insufficiency.

Factors associated with mortality: In all series, mortality rates were high in patients with cirrhosis and increased according to liver dysfunction [11,27,29,32]. Few studies compared patients with cirrhosis to control population and identifying prognostic factors is difficult due to the coexistence of IE and cirrhosis. Long term mortality data is difficult to analyze as mortality can be impacted not only by IE but also by the cirrhosis, its complications and the underlying cause of chronic liver disease (viral infections, chronic alcohol intake, metabolic features). That’s why we decided to discuss only data of in-hospital mortality. In the study of Pérez de Isla et al., no significant difference was observed regarding inhospital mortality (20% for patient with cirrhosis versus 17% for controls, p=NS). After age-adjusting analysis, cirrhosis was identified as an independent risk factor of mortality (OR=2.59; p=0.012). Nevertheless, no information about the severity of cirrhosis was available [32]. In the series of Fernández Guerrero et al., considering 31 patients with cirrhosis (Child-Pugh A: 12 patients, Child-Pugh B: 8 patients, Child-Pugh C: 11 patients), occurrence of renal failure (61.2% versus 16.1%, OR=8.23, p=0.001)and in-hospital mortality rate due to IE were significantly higher for patients with cirrhosis (51.6% versus 17.7%, OR=4.95, p=0.001) but no prognosis factors analysis was performed [28]. In the series of Hsu et al, the 7 in-hospital deceased patients (Child-Pugh A: 2 patients, Child-Pugh B: 1 patients, Child-Pugh C: 4 patients) with cirrhosis out of 26 presented more nosocomial disease (71% versus 11%, p=0.006), more Staphylococcus aureus infection (71% versus 21%, p=0.028), high uremia (57% versus 5%, p=0.01), and less aortic location (14% versus 79%, p=0.005) compared to living patients [29]. The largest series available presented by our group also supported a significant higher inhospital mortality rate related to IE in case of cirrhosis compared to control population (41.8% versus 23%, p=0.006). Prothrombin time (PT) ≤40% (p=0.001) and heart failure (p=0.03), were found to be independent risk factors of mortality in patients with cirrhosis [27]. Liver dysfunction reflected by a PT ≤40% and not cirrhosis alone should be considered as mortality risk factor.

Table 1: Modified Dukes criteria for diagnosis of infectious endocarditis (adapted from2015 ESC Guidelines(21)).

Major Criteria Positive blood culture
Two separate blood cultures positive for causative organisms
or
≥2Blood Cultures drawn >12 hours apart demonstrate causative organism
or
Blood cultures drawn with at least 3/3 or ≥3/4 positive for causative organism with ≥1 hour between first and last blood draw
or
Single Blood Culture positive for Coxiellaburneti or Phase 1 Immunoglobulin G antibody titer >1:800
Endocardial involvement
Paravalvular lesions by cardiac computed tomography
or
Positive Echocardiogram
Vegetation or
Intracardiac abscess or
Pseudoaneurysm or
Intracardiac fistula or
Valvular perforation or
New partial dehiscence of prosthetic valve
or
Abnormal activity around the site of prosthetic valve implantation detected by 18F-FDG positron emission tomography/ computed tomography or radiolabeled leukocytes single photon emission computerized tomography/ computed tomography
Minor Criteria Fever>38 °C
Predisposing condition
Heart valve disorder
Drug abuse
Immunologic findings
Glomerulonephritis
Osler’s Nodes
Roth’s spots
Rheumatoid factor
Microbiologic findings
Positive Blood Culture that does not meet major criteria
Serologic evidence of active infection with endocarditis causative organism
Vascular findings
Major arterial emboli
Septic pulmonary infarcts
Mycotic aneurysm
Intracranial hemorrhage
Conjunctival hemorrhage
Janeway’sLesion
Interpretation

Definitive Endocarditis Diagnosis
Pathology specimens from surgery or autopsy or
Two major criteria or
One major criteria and three minor criteria or
Five minor criteria

Possible Endocarditis Diagnosis
One major criteria and 1-2 minor criteria or
Three minor criteria

Table 2: Empirical antibiotics treatment strategy in case of suspicion of infectious endocarditis(adapted from 2015 ESC Guidelines (21)).

Community-acquired native valvesendocarditis or
Late prosthetic valves (≥12 months post surgery) endocarditis
Ampicillin + (Flu)cloxacillin or oxacillin + gentamicin
For penicillin-allergic patients: vancomycin +gentamicin
Nosocomial endocarditis or
Healthcare associated endocarditis or
Early prosthetic valves (<12 months post surgery) endocarditis
Vancomycin + gentamicin + Rifampin

Table 3: Causal microorganisms of infectious endocarditis in patients with cirrhosis and general population.

  Patients with cirrhosis General population
Gram-positive bacteria 74-100% 78-87%
Streptococci 10-39% 32-58%
Enterococci 6-19% 7-11%
Staphylococci    
Coagulase-negative staphylococci 4-6% 6-10%
Staphylococcus aureus 26-80% 23-27%
Gram-negative bacteria 3-5% 3-10%
Fungi 0-3% 1-2%

 

CONCLUSION

Cirrhosis is a risk factor for IE occurrence. Clinical and infectious features are close to general population with an increase of Gram-positive bacteria mostly due to nosocomial infections. In case of cirrhosis, IE is associated with poor outcome with high in-hospital mortality. Cardiac surgery, rarely performed at that time, should be considered for some eligible patients in order to improve survival.

REFERENCES

1. Arroyo V, Moreau R, Jalan R, Ginès P, EASL-CLIF Consortium CANONIC Study. Acute-on-chronic liver failure: A new syndrome that will reclassify cirrhosis. J Hepatol. 2015; 62: 131-143.

2. Sargenti K, Prytz H, Nilsson E, Kalaitzakis E. Predictors of mortality among patients with compensated and decompensated liver cirrhosis: the role of bacterial infections and infection-related acute-on-chronic liver failure. Scand J Gastroenterol. 2015; 50: 875-883.

3. Rosa H, Silvério AO, Perini RF, Arruda CB. Bacterial infection in cirrhotic patients and its relationship with alcohol. Am J Gastroenterol. 2000; 95: 1290-1293.

4. Fernández J, Ruiz del Arbol L, Gómez C, Durandez R, Serradilla R, Guarner C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006; 131: 1049-1056.

5. Elkrief L, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology. 2014; 60: 823-831. 

6. Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015; 35: 362-369.

7. Nahon P, Lescat M, Layese R, Bourcier V, Talmat N, Allam S, et al. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort). Gut. 2017; 66: 330- 341.

8. Arvaniti V, D’Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, et al. Infections in patients with cirrhosis increase mortality fourfold and should be used in determining prognosis. Gastroenterology. 2010; 139: 1246-1256.

9. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology. 2009; 50: 2022-2033.

10. Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol. 2007; 102: 1510-1517.

11. Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002; 35: 140-148.

12. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014; 60: 1310-1324.

13. Bunchorntavakul C, Chavalitdhamrong D. Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World J Hepatol. 2012; 4: 158-168.

14. Moreillon P, Que YA. Infective endocarditis. Lancet. 2004; 363: 139- 149.

15. Cahill TJ, Prendergast BD. Current controversies in infective endocarditis. F1000Res. 2015; 4.

16. Hoen B, Alla F, Selton-Suty C, Béguinot I, Bouvet A, Briançon S, et al. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA. 2002; 288: 75-81.

17. Fernández-Hidalgo N, Tornos Mas P. Epidemiology of infective endocarditis in Spain in the last 20 years. Rev Esp Cardiol (Engl Ed). 2013; 728-733.

18. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on EndocarditisProspective Cohort Study. Arch Intern Med. 2009; 169: 463-473.

19. Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis. 2012; 54: 1230-1239.

20. Gould FK, Denning DW, Elliott TSJ, Foweraker J, Perry JD, Prendergast BD, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2012; 67: 269-289.

21. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 2015; 36: 3075-3128.

22. Leone S, Ravasio V, Durante-Mangoni E, Crapis M, Carosi G, Scotton PG, et al. Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian Study on Endocarditis. Infection. 2012; 40: 527-535.

23. Ratnoff O, Patek A. The natural history of Laennec’s cirrhosis of the liver: analysis of 386 cases. Medicine. 1947; 3: 207-268.

24. Snyder N, Atterbury CE, Pinto Correia J, Conn HO. Increased concurrence of cirrhosis and bacterial endocarditis. A clinical and postmortem study. Gastroenterology. 1977; 73: 1107-1113.

25. Denton JH, Rubio C, Velázquez J, de Arellano GR. Bacterial endocarditis in cirrhosis. Dig Dis Sci. 1981; 26: 935-937.

26. Hung TH, Hsieh YH, Tseng KC, Tsai CC, Tsai CC. The risk for bacterial endocarditis in cirrhotic patients: a population-based 3-year followup study. Int J Infect Dis. 2013; 17: 391-393.

27. Cadranel JF, Ollivier-Hourmand I, Allaire M, Zerkly S, Bureau C, Thovenot R, et al. Liver insufficiency is associated with mortality in patients with cirrhosis and infectious endocarditis: a case control multicenter study of 202 cases. 2017; in press.

28. Fernández Guerrero ML, González López J, Górgolas M. Infectious endocarditis in patients with cirrhosis of the liver: a model of infection in the frail patient. Eur J Clin Microbiol Infect Dis. 2010; 29: 1271- 1275.

29. Hsu RB, Chen RJ, Chu SH. Infective endocarditis in patients with liver cirrhosis. J Formos Med Assoc. 2004; 103: 355-358.

30. McCashland TM, Sorrell MF, Zetterman RK. Bacterial endocarditis in patients with chronic liver disease. Am J Gastroenterol. 1994; 89: 924- 927.

31. Oksenberg RD, Castelli TA, Fica CA. [Infective endocarditis in patients with chronic hepatic failure: a four cases series]. Rev Chilena Infectol. 2009; 26: 258-262.

32. Pérez De Isla L, Zamorano JL, Almería C, Rodrigo JL, Piedra I, Aubele A, et al. [Infective endocarditis in patients with chronic liver disease: clinical and prognostic assessment]. Rev Esp Cardiol. 2003; 56: 794- 800.

33. Finkielman JD, Gimenez M, Pietrangelo C, Blanco MV. Endocarditis as a complication of a transjugular intrahepatic portosystemic stentshunt. Clin Infect Dis. 1996 Feb; 22: 385-386.

34. Zhang X, Liu X, Yang M, Dong H, Xv L, Li L. Occurrence of infective endocarditis following endoscopic variceal ligation therapy: A case report. Medicine (Baltimore). 2016; 95: 4482.

35. Bizouarn P, Ausseur A, Desseigne P, Le Teurnier Y, Nougarede B, Train M, et al. Early and late outcome after elective cardiac surgery in patients with cirrhosis. Ann Thorac Surg. 1999; 67: 1334-1338.

36. Kaplan M, Cimen S, Kut MS, Demirtas MM. Cardiac operations for patients with chronic liver disease. Heart Surg Forum. 2002; 5: 60-65.

Allaire M, Ollivier-Hourmand I, Garrioud A, Dao T, Cadranel JF (2017) Infectious Endocarditis in Patients with Cirrhosis: Epidemiology, Characteristics and Outcome. JSM Gastroenterol Hepatol 5(1): 1077.

Received : 12 Jan 2017
Accepted : 16 Feb 2017
Published : 20 Feb 2017
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X